Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4818972 | 0.98 | TSHR (0.31) | TSHRNLRP3 | |
| SCHEMBL566248 | 0.93 | TSHR (0.31) | TSHR | |
| SCHEMBL10030503 | 0.93 | TSHR (0.35) | TSHR | |
| SCHEMBL14136628 | 0.92 | TSHR (0.30) | TSHRNLRP3 | |
| SCHEMBL2621446 | 0.92 | TSHR (0.30) | TSHRNLRP3 | |
| SCHEMBL16504168 | 0.92 | TSHR (0.30) | TSHRNLRP3 | |
| SCHEMBL18541723 | 0.91 | — | — | |
| SCHEMBL22743730 | 0.91 | NLRP3 (0.31) | NLRP3 | |
| SCHEMBL2397817 | 0.91 | — | — | |
| SCHEMBL17133199 | 0.91 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 818 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119490394-A | Isobutene hydroformylation catalytic system and method for catalytic synthesis of isovaleraldehyde | 宁夏天新药业有限公司 | 2025-02-21 | — | — | CN | claimed |
| CN-119080856-A | Mutant tRNA for codon extension | 中外制药株式会社 | 2024-12-06 | — | — | CN | claimed |
| CN-118178675-A | Supermolecule DNA-PEG-Ferrocene nano gel, preparation method and anti-tumor application | 武汉科技大学 | 2024-06-14 | — | — | CN | claimed |
| EP-4367244-A1 | OLIGONUCLEOTIDE-BASED DELIVERY VEHICLE FOR OLIGONUCLEOTIDES AGENTS AND METHODS OF USE THEREOF | Ractigen Therapeutics (CN) | 2024-05-15 | — | — | EP | claimed |
| CN-117916374-A | Oligonucleotide-based delivery vehicles for oligonucleotide agents and methods of use thereof | 中美瑞康核酸技术(南通)研究院有限公司 | 2024-04-19 | — | — | CN | claimed |
| EP-4341270-A1 | CHEMICAL PHOSPHORYLATION REAGENTS, PREPARATION, AND THEIR USES | Olix US, Inc. (US) | 2024-03-27 | — | — | EP | claimed |
| CN-117580848-A | Chemical phosphorylating reagent, preparation and use thereof | 奥利克斯美国公司 | 2024-02-20 | — | — | CN | claimed |
| CN-114941018-B | Synthesis method of cap1 cap analogue | 翌圣生物科技(上海)股份有限公司 | 2023-09-22 | — | — | CN | claimed |
| WO-2023280190-A1 | OLIGONUCLEOTIDE-BASED DELIVERY VEHICLE FOR OLIGONUCLEOTIDES AGENTS AND METHODS OF USE THEREOF | RACTIGEN THERAPEUTICS (CN) | 2023-01-12 | — | — | WO | claimed |
| US-20230000983-A1 | METHODS AND COMPOSITIONS FOR SYNTHESIS OF TWO-PHOTON CLEAVABLE PHOSPHORAMIDITE MOLECULES FOR OLIGONUCLEOTIDE CONJUGATION | CITY UNIVERSITY OF HONG KONG (HK) | 2023-01-05 | — | — | US | claimed |
| EP-3095790-A1 | NUCLEOSIDE-LIPID COMPOUNDS WITH PH-SENSITIVE DIALKYLORTHOESTER CHAINS AND THEIR USE FOR TRANSPORTATION OR VECTORIZATION OF AT LEAST ONE THERAPEUTIC AGENT | UNIVERSITE DE BORDEAUX (FR) | 2016-11-23 | — | — | EP | claimed |
| EP-2767541-A1 | LPA receptor agonists and antagonists | Rxbio, Inc. (US) | 2014-08-20 | — | — | EP | claimed |
| US-8461124-B2 | Five- and six-membered conformationally locked 2′,4′-carbocyclic ribo-thymidines for the treatment of infections and cancer | CHATTOPADHYAYA JYOTI (SE) | 2013-06-11 | — | — | US | claimed |
| JP-4237257-B2 | — | — | 2009-03-11 | — | — | JP | claimed |
| EP-1021388-B1 | PHOSPHORYLATION PROCESS AND CATALYST | BIONERIS AB (SE) | 2003-06-25 | — | — | EP | claimed |
| US-6479656-B1 | Phosphorylation process and catalyst | PERSTORP AB (SE) | 2002-11-12 | — | — | US | claimed |
| JP-2001501910-A | — | — | 2001-02-13 | — | — | JP | claimed |
| EP-1021388-A1 | PHOSPHORYLATION PROCESS AND CATALYST | PERSTORP AB (SE) | 2000-07-26 | — | — | EP | claimed |
| WO-1997034853-A1 | PHOSPHORYLATION PROCESS AND CATALYST | PERSTORP AB (SE) | 1997-09-25 | — | — | WO | claimed |
| US-5430169-A | Method for preparation of sphingoid bases | THE UNITED STATES OF AMERICA REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1995-07-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230000983-A1 | METHODS AND COMPOSITIONS FOR SYNTHESIS OF TWO-PHOTON CLEAVABLE PHOSPHORAMIDITE MOLECULES FOR OLIGONUCLEOTIDE CONJUGATION | PCNA, POLB, NCL | TSHR 3117/4885NLRP3 3872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.